For these reasons, we aimed to characterize the role of BRAF‐V600E mutation in modulation of PD‐L1 and Gal‐1 expression and to further investigate potential immunoregulatory properties of BRAF inhibitors in melanoma. This evidence concerns the gene LGALS1 and melanoma.